Evabosmig (AGA2118) is a humanized bispecific monoclonal antibody targeting sclerostin ( SOST/sclerostin ) and DKK1. SOST and DKK1 are two key secreted negative regulators of the intramedullary Wnt/β-catenin pathway. Evabosmig possesses activities to induce bone formation, inhibit bone resorption and increase bone mineral density. Evabosmig is applicable for research related to osteoporosis [1] [2].
In Vivo, Evabosmig promotes bone formation and inhibits bone resorption in animal models, thereby rapidly increasing bone mineral density (BMD)[1].
References:
[1]. Drake, M. T., et al. (2024, September). AGA2118, a bispecific monoclonal antibody neutralizing both sclerostin and DKK1, increased bone Formation, decreased bone resorption, and led to rapid BMD gains in a first in human, single-and multiple-dose, placebo-controlled, randomized study. In ASBMR 2024 Annual Meeting. ASBMR.
[2]. Adami G, et al. Increase in serum DKK1 levels attenuates the anabolic response to romosozumab in postmenopausal osteoporosis. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2026 Feb 03;41(2):143-149.
In Vivo, Evabosmig promotes bone formation and inhibits bone resorption in animal models, thereby rapidly increasing bone mineral density (BMD)[1].
References:
[1]. Drake, M. T., et al. (2024, September). AGA2118, a bispecific monoclonal antibody neutralizing both sclerostin and DKK1, increased bone Formation, decreased bone resorption, and led to rapid BMD gains in a first in human, single-and multiple-dose, placebo-controlled, randomized study. In ASBMR 2024 Annual Meeting. ASBMR.
[2]. Adami G, et al. Increase in serum DKK1 levels attenuates the anabolic response to romosozumab in postmenopausal osteoporosis. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2026 Feb 03;41(2):143-149.